pegozafermin (BIO89-100) / 89Bio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegozafermin (BIO89-100) / 89Bio
NCT04541186: Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Completed
2
86
Europe, US, RoW
Pegozafermin, BIO89-100, Placebo
89bio, Inc.
Severe Hypertriglyceridemia
05/22
05/22
ENLIVEN, NCT04929483: Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Active, not recruiting
2
222
US
BIO89-100, Placebo
89bio, Inc.
NASH - Nonalcoholic Steatohepatitis
02/23
09/24
2020-000641-13: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia

Not yet recruiting
2
90
Europe, RoW
BIO89-100, BIO89-100, Solution for injection
89bio, Inc., 89bio, Inc.
Severe Hypertriglyceridemia (SHTG), Severe Hypertriglyceridemia (SHTG), Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04048135: A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Completed
1/2
101
US
Pegozafermin, BIO89-100, Placebo
89bio, Inc., ProSciento, Inc.
NASH
08/20
01/22

Download Options